Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference [Yahoo! Finance]
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Yahoo! Finance
Enanta plans a Phase 3 adult study of zelicapavir (N-protein RSV inhibitor) focused on the high-risk “HR3” subgroup (age 75 or COPD/CHF) with a symptom-based RiiQ primary endpoint and ~600–700 patients; Phase 2 showed ~7-day shorter symptom duration and about a 50% reduction in hospitalizations versus placebo. The second RSV candidate, EDP-323 (L-protein polymerase inhibitor), produced very rapid viral-load reductions in human challenge studies—cultured virus was “obliterated” within 12 hours—and could serve as a next-generation asset, part of combination strategies, or for post-exposure prophylaxis. Enanta is building an oral immunology portfolio (KIT/EDP-978, STAT6/EDP-3903, and MRGPRX2) with IND and candidate-selection milestones in 2024, and holds $242 million in cash providing runway into fiscal 2029. Interested in Enanta Pharmaceuticals, Inc.? Here are five stocks we like better. Enanta Pharmaceuticals (NASDAQ:ENTA) used a presentation at the Citizens Life Sciences Conf
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences ConferenceBusiness Wire
- Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual MeetingBusiness Wire
- Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ENTA
Earnings
- 2/9/26 - Beat
ENTA
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- ENTA's page on the SEC website